-transparent.png){kind=logo}
Despite the efforts of many workers, the cause and therapy has not been clarified. We carried out the therapeutic trial of thyrotropin releasing hormone (TRH) for amyotrophic lateral sclerosis (ALS) from January, 1979 to January, 1983. There were 16 subjects. The patients were given a low dose (0.5-2 mg) of TRH intravenously or intramusculary. Mild to moderate improvement was found in 9 (56%) of 16 patients. TRH has been reported to have the activating effects on the pyramidal tract, brainstem motor nuclei, and motoneuron in the spinal cord as a neurotransmitter or neuromodulator. We thought such action of TRH to be useful to the therapy of ALS.
Related Publications
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
January 1986,
Revue neurologique,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
January 1987,
Advances in experimental medicine and biology,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
February 1987,
Neurologic clinics,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
January 1985,
Journal of neurology,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
February 1986,
Neurology,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
September 1984,
Lancet (London, England),
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
January 1991,
Rinsho shinkeigaku = Clinical neurology,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
May 1987,
Neurologic clinics,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
January 1988,
Annals of the New York Academy of Sciences,
K Yamane, and
M Osawa, and
I Kobayashi, and
S Maruyama
January 1988,
Neurologia i neurochirurgia polska,
